Patent 5447724 Issued on September 5, 1995. Estimated Expiration Date: November 15, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
424/426, Errodable, resorbable, or dissolving424/423, Surgical implant or material424/424, Membrane or diffusion barrier424/425, Diffusion barrier is matrix424/450, Liposomes427/2.12, For contacting living body or transfusing bodily fluid (e.g., endoscope, electrode, thermometer, probe)514/772.2, Polyvinyl alcohol514/822, ANTICOAGULATION523/112, Non-thrombogenic523/113, Composition suitable for use as tissue or body member replacement, restorative, or implant604/266, With anticlogging means on conduit (e.g., anticlotting, decalcification, tissue occulsion, etc.)604/507Therapeutic material introduced into or removed from vasculature
A medical device and a method for its manufacture. The function of the medical device requires exposure of the device to the tissue of a patient. The device has a tissue-exposed portion constructed to release an agent that inhibits adverse reaction to the presence of the device defined by a polymeric surface-layer overlying in a supported manner a polymer defining a reservoir. The reservoir incorporates the agent in a manner that permits substantially free outward release of the agent from the reservoir and the overlying layer defines metering outward passages constructed to control the outward migration of the agent to enable prolonged release of the agent from the surface of the medical device to prevent the adverse reaction due to the presence of the device.
Other References
Brown, "Controlled Release of Insulin from Polymer Matrices In Vitro Kinetics" Diabetes, v. 35, Jun. 1986, p. 684
Ebert, Medical Applications of Controlled Release, v. 2, chapter 4, p. 77
Edelmann, "Polymer Matrix Based Controlled Adventitial Delivery of Antiproliferative Agents and Regulation og the Vascular Response to Injury"
Kim, "Heparinized Polymers for Improving Blood Compatability", MD and DI, Aug. 1984, p. 99
Kim et al., "Heparin Release from Hydrophobic Polymers: (1) In Vitro Studies", Arch. Phar. Research, 9(4) 193-199 (1986)
Lin, "Minimum Heparin Release Rate for Nonthrombogenicity", Trans. Am. Soc. Artif. Intern. Organs vol. XXXIII, 1987, p. 602
Mcrea, "Prostaglandin Releasing Polymers-Stability and Efficacy", Trans. Am. Soc. Artif. Inter. Organs, vol. XXVII, 1981, p. 511
Miyama, "A New Antithrombogenic Heparinized Polymer", J. Biomed. Mater. Res., vol. 11, pp. 251-265 (1977)
Noishiki, "Prevention of Thrombosis Related Complications in Cardiac Characterization and Angiography Using a Heparinized Catheter (Anthron.RTM.)", ASAIO, Jul.-Sep. 1987, p. 359
Rhine, "Polymers for Sustained Macromolecular Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics", Journal of Pharm. Sciences, vol. 69, No. 3, Mar. 1980
Ritchel, "Permeability of [3 H] Water Across A Porous Polymer Matrix Used As A Rate-Limiting Shell in Compression-coated Tablets", J. Controlled Release, 12 (1990) 97-102
Sparks, "Reduction of Platelet Deposition on Vascular Graphs Using an Antiplatelet Graft Coating Technique", Abstract in Journal of Surgical Research, 33, 367/373 (1982)
Technical note: "Literature Review of the Use of Heparinized Polyurethane Catheters: Comparison to Silicone and Non-Heparinized Catheters"
November 15, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
